R1 RCM Inc. (NASDAQ:RCM) Shares Sold by US Bancorp DE

US Bancorp DE lowered its stake in R1 RCM Inc. (NASDAQ:RCM) by 68.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,605 shares of the healthcare provider’s stock after selling 5,668 shares during the quarter. US Bancorp DE’s holdings in R1 RCM were worth $37,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Advisors Asset Management Inc. purchased a new stake in shares of R1 RCM in the 1st quarter valued at approximately $27,000. GAMMA Investing LLC raised its position in R1 RCM by 41.3% in the third quarter. GAMMA Investing LLC now owns 2,597 shares of the healthcare provider’s stock valued at $37,000 after purchasing an additional 759 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in R1 RCM by 589.2% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,122 shares of the healthcare provider’s stock worth $44,000 after purchasing an additional 2,669 shares in the last quarter. ANTIPODES PARTNERS Ltd purchased a new position in shares of R1 RCM during the second quarter worth $86,000. Finally, Values First Advisors Inc. purchased a new position in shares of R1 RCM during the third quarter worth $88,000. Hedge funds and other institutional investors own 61.10% of the company’s stock.

R1 RCM Trading Up 0.1 %

RCM opened at $14.31 on Tuesday. The business’s 50-day simple moving average is $14.22 and its 200-day simple moving average is $13.42. The company has a market cap of $6.04 billion, a P/E ratio of -95.39 and a beta of 0.84. R1 RCM Inc. has a one year low of $8.87 and a one year high of $15.12. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.79 and a current ratio of 1.79.

R1 RCM (NASDAQ:RCM) last issued its quarterly earnings data on Tuesday, November 5th. The healthcare provider reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.04). R1 RCM had a negative return on equity of 2.18% and a negative net margin of 2.48%. The business had revenue of $656.80 million for the quarter, compared to analysts’ expectations of $640.93 million. R1 RCM’s quarterly revenue was up 14.7% on a year-over-year basis. As a group, equities research analysts expect that R1 RCM Inc. will post -0.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on RCM shares. Jefferies Financial Group lowered R1 RCM from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Leerink Partners lowered shares of R1 RCM from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $17.00 to $14.30 in a research note on Thursday, August 1st. TD Cowen reaffirmed a “hold” rating and set a $14.30 target price (down from $20.00) on shares of R1 RCM in a research note on Monday, August 5th. Morgan Stanley lowered shares of R1 RCM from an “overweight” rating to an “equal weight” rating in a report on Thursday, August 8th. Finally, Truist Financial dropped their price target on shares of R1 RCM from $16.00 to $14.30 and set a “hold” rating for the company in a research note on Thursday, August 8th. Thirteen equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $15.41.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.